vs
Side-by-side financial comparison of Civeo Corp (CVEO) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $161.6M, roughly 1.7× Civeo Corp). Civeo Corp runs the higher net margin — -4.0% vs -45.7%, a 41.7% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 7.1%). Civeo Corp produced more free cash flow last quarter ($14.5M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -1.4%).
The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CVEO vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $161.6M | $281.3M |
| Net Profit | $-6.5M | $-128.5M |
| Gross Margin | 22.7% | 64.6% |
| Operating Margin | -0.1% | -43.0% |
| Net Margin | -4.0% | -45.7% |
| Revenue YoY | 7.1% | 39.4% |
| Net Profit YoY | 58.1% | -15.8% |
| EPS (diluted) | $-0.58 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $161.6M | $281.3M | ||
| Q3 25 | $170.5M | $265.2M | ||
| Q2 25 | $162.7M | $232.1M | ||
| Q1 25 | $144.0M | $203.5M | ||
| Q4 24 | $151.0M | $201.8M | ||
| Q3 24 | $176.3M | $191.5M | ||
| Q2 24 | $188.7M | $177.2M | ||
| Q1 24 | $166.1M | $168.5M |
| Q4 25 | $-6.5M | $-128.5M | ||
| Q3 25 | $-455.0K | $-92.7M | ||
| Q2 25 | $-3.3M | $-99.9M | ||
| Q1 25 | $-9.8M | $-95.2M | ||
| Q4 24 | $-15.4M | $-111.0M | ||
| Q3 24 | $-5.1M | $-107.8M | ||
| Q2 24 | $8.2M | $-102.6M | ||
| Q1 24 | $-5.1M | $-115.0M |
| Q4 25 | 22.7% | 64.6% | ||
| Q3 25 | 25.7% | 64.7% | ||
| Q2 25 | 25.3% | 65.0% | ||
| Q1 25 | 20.4% | 63.3% | ||
| Q4 24 | 18.6% | 61.6% | ||
| Q3 24 | 21.4% | 61.1% | ||
| Q2 24 | 25.4% | 59.1% | ||
| Q1 24 | 21.5% | 61.2% |
| Q4 25 | -0.1% | -43.0% | ||
| Q3 25 | 4.1% | -37.3% | ||
| Q2 25 | 1.7% | -45.9% | ||
| Q1 25 | -3.8% | -54.6% | ||
| Q4 24 | -6.7% | -62.4% | ||
| Q3 24 | 0.0% | -61.3% | ||
| Q2 24 | 6.9% | -56.8% | ||
| Q1 24 | -1.1% | -59.2% |
| Q4 25 | -4.0% | -45.7% | ||
| Q3 25 | -0.3% | -35.0% | ||
| Q2 25 | -2.0% | -43.0% | ||
| Q1 25 | -6.8% | -46.8% | ||
| Q4 24 | -10.2% | -55.0% | ||
| Q3 24 | -2.9% | -56.3% | ||
| Q2 24 | 4.4% | -57.9% | ||
| Q1 24 | -3.1% | -68.2% |
| Q4 25 | $-0.58 | $-1.01 | ||
| Q3 25 | $-0.04 | $-0.74 | ||
| Q2 25 | $-0.25 | $-0.80 | ||
| Q1 25 | $-0.72 | $-0.77 | ||
| Q4 24 | $-1.04 | $-0.90 | ||
| Q3 24 | $-0.36 | $-0.88 | ||
| Q2 24 | $0.56 | $-0.84 | ||
| Q1 24 | $-0.35 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $174.4M | $-99.3M |
| Total Assets | $477.4M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $378.2M | ||
| Q3 25 | $12.0M | $580.0M | ||
| Q2 25 | $14.6M | $629.1M | ||
| Q1 25 | $28.4M | $698.6M | ||
| Q4 24 | $5.2M | $525.5M | ||
| Q3 24 | $17.9M | $585.0M | ||
| Q2 24 | $7.4M | $933.7M | ||
| Q1 24 | $16.8M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $43.3M | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $174.4M | $-99.3M | ||
| Q3 25 | $182.5M | $-354.5M | ||
| Q2 25 | $209.4M | $-305.5M | ||
| Q1 25 | $220.7M | $-250.8M | ||
| Q4 24 | $236.4M | $-139.6M | ||
| Q3 24 | $282.2M | $-60.1M | ||
| Q2 24 | $297.4M | $-1.6M | ||
| Q1 24 | $297.4M | $68.3M |
| Q4 25 | $477.4M | $2.0B | ||
| Q3 25 | $491.1M | $1.3B | ||
| Q2 25 | $508.8M | $1.3B | ||
| Q1 25 | $423.8M | $1.3B | ||
| Q4 24 | $405.1M | $1.5B | ||
| Q3 24 | $477.6M | $1.5B | ||
| Q2 24 | $483.2M | $1.6B | ||
| Q1 24 | $513.1M | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.3M | $-26.4M |
| Free Cash FlowOCF − Capex | $14.5M | $-54.2M |
| FCF MarginFCF / Revenue | 8.9% | -19.3% |
| Capex IntensityCapex / Revenue | 3.0% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.3M | $-26.4M | ||
| Q3 25 | $13.8M | $-35.4M | ||
| Q2 25 | $-2.3M | $-60.3M | ||
| Q1 25 | $-8.4M | $-62.7M | ||
| Q4 24 | $9.5M | $-64.5M | ||
| Q3 24 | $35.7M | $-51.1M | ||
| Q2 24 | $32.4M | $-94.0M | ||
| Q1 24 | $6.0M | $-30.3M |
| Q4 25 | $14.5M | $-54.2M | ||
| Q3 25 | $8.2M | $-45.8M | ||
| Q2 25 | $-6.8M | $-65.9M | ||
| Q1 25 | $-13.7M | $-67.1M | ||
| Q4 24 | $1.8M | $-83.4M | ||
| Q3 24 | $28.2M | $-55.3M | ||
| Q2 24 | $27.0M | $-99.1M | ||
| Q1 24 | $372.0K | $-37.2M |
| Q4 25 | 8.9% | -19.3% | ||
| Q3 25 | 4.8% | -17.3% | ||
| Q2 25 | -4.2% | -28.4% | ||
| Q1 25 | -9.5% | -33.0% | ||
| Q4 24 | 1.2% | -41.3% | ||
| Q3 24 | 16.0% | -28.9% | ||
| Q2 24 | 14.3% | -55.9% | ||
| Q1 24 | 0.2% | -22.1% |
| Q4 25 | 3.0% | 9.9% | ||
| Q3 25 | 3.3% | 3.9% | ||
| Q2 25 | 2.8% | 2.4% | ||
| Q1 25 | 3.7% | 2.2% | ||
| Q4 24 | 5.1% | 9.4% | ||
| Q3 24 | 4.2% | 2.2% | ||
| Q2 24 | 2.8% | 2.9% | ||
| Q1 24 | 3.4% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.93× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CVEO
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
